LLY241206C980000
- 0.60
- 0.000.00%
Eli Lilly and Co Newsroom
Eli Lilly Says Imlunestrant Improved Progression-Free Survival in Phase 3 Breast Cancer Study
Trump is reportedly set to ring the bell at the NYSE today. What does it signify?
① According to media reports, the USA's incoming president Trump will go to the NYSE on Thursday to ring the opening bell and deliver a speech; ② There are reports that Trump will be named Time Magazine's Person of the Year for 2024, but this has not yet been confirmed by Time; ③ Since Trump's announcement of victory, the three major US stock indices have risen repeatedly, with the market encouraged by promises of tax cuts and deregulation.
Eli Lilly (LLY) Stock Slides as Market Rises: Facts to Know Before You Trade
Jim Cramer Says He Would Prefer Eli Lilly (LLY) Over Regeneron Even at $900
Eli Lilly's Investigational Cancer Drug Cuts Risk Of Death By 38% In Breast Cancer Patients
'Eli Lilly to Sell Zepbound Through Telehealth Company Ro' - Barron's
Eli Lilly Ties Up With Ro to Improve Availability of Weight-Loss Drug Zepbound in Vials
Market Climbs on CPI Inflation and Likelihood of Rate Cuts | Livestock
BofA Securities Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $997
Eli Lilly Unusual Options Activity
Express News | Ro Works With Lilly to Streamline Patient Access to Authentic Zepbound Single-Dose Vials by Integrating With Lilly's Pharmacy Channel
Express News | Lilly's Imlunestrant, an Oral Serd, Significantly Improved Progression-Free Survival as Monotherapy and in Combination With Verzenio® (Abemaciclib) in Patients With Er+, Her2- Advanced Breast Cancer
Express News | Ro: Vials to Be Available With on-Label Prescription From a Ro-Affiliated Provider via Integration With Lillydirect Self-Pay Pharmacy Channel
Bank of America: Resuming coverage of Eli Lilly and Co, rating it as 'Buy'.
Bank of America resumes coverage on Eli Lilly and Co, assigning a "Buy" rating with a Target Price of $997.
BofA Securities Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Cuts Target Price to $997
Lilly's Imlunestrant, an Oral SERD, Significantly Improved Progression-Free Survival as Monotherapy and in Combination With Verzenio (Abemaciclib) in Patients With ER+, HER2- Advanced Breast Cancer
Eli Lilly and Co (LLY.US) seeks to expand the indications for its weight loss medication and will conduct trials to treat addictive behaviors.
Eli Lilly and Co will test a weight loss drug for treating addiction in 2025.
BofA Restarts Coverage of 11 Large-cap Biopharmas
Market Falls Wednesday, but Googles Chip Impresses | WST
Eli Lilly's $15 Billion Buyback Faces Stiff Resistance On The Charts